Gentex Corporation led the first close of PhotoniCare Inc.'s $4.6 million Series B financing round and simultaneously became a manufacturing partner for PhotoniCare's FDA-cleared OtoSight™ Middle Ear Scope. This investment supports PhotoniCare's clinical trials, production ramp-up, and sales efforts.
The OtoSight Middle Ear Scope utilizes optical coherence tomography (OCT) high-resolution depth imaging to detect and characterize fluid in the middle ear, even in the presence of ear wax. This technology aims to improve the diagnosis, treatment, and monitoring of middle ear infections, which affect over 80% of children.
PhotoniCare is relocating its headquarters to Grand Rapids, Michigan, to facilitate closer collaboration with Gentex. This partnership allows Gentex to leverage its optical, sensing, and manufacturing capabilities in the medical device sector, expanding its diversification strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.